Alzheimer's disease is a complex neurodegenerative disorder, yet not a typical aspect of aging.¹ It is the leading cause of dementia in older adults, affecting nearly seven million Americans.² Diagnosis traditionally relies on detecting amyloid plaques and tau tangles in the brain—which, until recently, required costly and invasive procedures such as advanced brain imaging or cerebrospinal fluid tests. Emerging technologies offer promising methods for detecting these biomarkers, potentially allowing for earlier and more accurate diagnosis, even before cognitive symptoms appear, enhancing both patient and provider understanding of the disease's underlying biology. Most importantly, this information can provide access to new therapeutics and the understanding that lifestyle changes can have a measurable benefit.